StockData
BeOne Medicines Ltd. logo

BeOne Medicines Ltd.

ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302252% above fair value
$361.27−9.06 (-2.45%)

Close on Nov 2, 2026Market cap $41.08BP/E 64.6Yield –

BeOne Medicines Non-GAAP Adjusted Operating Income (Loss) by Year

Non-GAAP Adjusted Operating Income (Loss) ($M) ($M)

BeOne Medicines Non-GAAP Adjusted Operating Income (Loss): $1,100M in FY2025, up 2,325.2% from a year earlier.

Latest, FY2025
1,100
Period ended Dec 31, 2025
Change on a year earlier
+2,325.2%
45.4 in FY2024
History
4 years
Since FY2022
Sources
3
Documents cited below

Where the FY2025 figure comes from

“|| Adjusted income from operations | $ | 344,476 | $ | 78,603 | $ | 1,099,962 | $ | 45,356”

Source: Form 8-K (filed 2026-02-26) ↗

Reported in Form 8-K EX-99.1 Non-GAAP Reconciliation Tables.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNon-GAAP Adjusted Operating Income (Loss) ($M) ($M)Year on yearSource
FY2025Dec 31, 20251,100+2,325.2%Form 8-K (filed 2026-02-26) ↗
FY2024Dec 31, 202445.4-106.0%Form 8-K (filed 2025-02-27) ↗
FY2023Dec 31, 2023-752-47.0%Form 8-K (filed 2024-02-26) ↗
FY2022Dec 31, 2022-1,420–Form 8-K (filed 2024-02-26) ↗

Breakdown

What makes up non-GAAP Adjusted Operating Income (Loss)

Cite this data

StockData. (2026). BeOne Medicines Non-GAAP Adjusted Operating Income (Loss) ($M), annual FY2022–FY2025 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/adj-op-inc

See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.